| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1214
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-12 |
| filingDate |
2010-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2012-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-WO2010104052-A1 |
| titleOfInvention |
Humanized PcrV antibody having anti-Pseudomonas aeruginosa action |
| abstract |
As an effective means for treating infections, particularly infections caused by Pseudomonas aeruginosa, a humanized monoclonal antibody against PcrV or a part thereof, and a pharmaceutical composition containing these as active ingredients are provided. Specifically, the humanized monoclonal antibody of the present invention has excellent cytotoxic inhibitory activity against target cells of Pseudomonas aeruginosa. In addition, the humanized monoclonal antibody of the present invention has a high affinity for PcrV. |
| priorityDate |
2009-03-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |